Sign inJoin waitlistJoin the waitlist

Nicholas Pytel

Assistant Professor · University of Wisconsin School of Medicine and Public Health

Credentials: · · · ·

History

University of Wisconsin School of Medicine and Public Health
Present

St Jude Children's Research Hospital
2018–2019
Pediatric Hematology Oncology
University of Wisconsin School of Medicine and Public Health
2017–2018
Pediatrics
University of Wisconsin Hospitals and Clinics
2014–2017
University of Illinois, Urbana, Illinois
Arizona College of Osteopathic Medicine
2010–2014

Research

Structural polymorphism in the N-terminal oligomerization domain of NPM1
Proceedings of the National Academy of Sciences of the United States of America · 2014 · 171 citations
Triggered drug release from dynamic microspheres via a protein conformational change
Macromolecular Bioscience · 2010 · 24 citations
A CTNNB1-altered medulloblastoma shows the immunophenotypic, DNA methylation and transcriptomic profiles of SHH-activated, and not WNT-activated, medulloblastoma
Neuropathology and Applied Neurobiology · 2022 · 5 citations

Larissa Furtado
2 papers
Angela Viaene
1 paper
Asim Bag
1 paper
Brent Orr
1 paper
BM
Brett Morris
1 paper
Daniel Moreira Ridsdale
1 paper
Emily Hanzlik
1 paper · 1 as a fellow
Jason Chiang
1 paper
Jennifer Kalish
1 paper
Julieann Lee
1 paper
Lu Wang
1 paper
Melissa Perrino
1 paper · 1 as a fellow

Clinical trials

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Site PI · Recruiting · Phase 2
Children's Oncology Group
2024–2033
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Site PI · Recruiting · Phase 3
Children's Oncology Group
2023–2029
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2022–2027
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Site PI · Recruiting · Phase 2
Children's Oncology Group
2021–2029